Canagliflozin clinical trials
Also written Invokana and JNJ-28431754.
How each study uses Canagliflozin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Canagliflozin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Mar 2013 · INVOKANA · NDA 204042 (FDA, Drugs@FDA)
- European Union
- 15 Nov 2013 · Invokana · EMEA/H/C/002649 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
121 studies that test it; most in 2014 (18); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 9 |
| 2009 | 4 |
| 2010 | 12 |
| 2011 | 16 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 18 |
| 2015 | 3 |
| 2016 | 11 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 80 · Other 42
Janssen Research & Development, LLC (37) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (28) · Tanabe Pharma Corporation (9) · University of Maryland, Baltimore (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · The University of Texas Health Science Center at San Antonio (2) · Janssen-Cilag International NV (2) · West China Hospital (2)
Often tested with
Tested in the same studies.
Metformin (15) · Sitagliptin (6) · Empagliflozin (5) · Dapagliflozin (5) · Pioglitazone (3) · Extended Release Metformin Hydrochloride (3) · Vildagliptin (2) · Sotagliflozin (2)
Related medicines
As reviewed, each with the page that says it.
- One of SGLT2 inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test Canagliflozin, phase 3 first.
- Dec 2026Canagliflozin Targeting Vascular InflammationPhase 2/3 · Ottawa Heart Institute Research Corporation
- Dec 2026Renal Mechanism of SGLT2 InhibitionPhase 2 · University of Colorado, Denver
- Jan 2027CANagliflozin In DIALysis PatientsPhase 4 · University Medical Center Groningen
- Jul 2027The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseasePhase 2 · National Taiwan University Hospital
- Oct 2027SGLT2 Inhibitor Utilization Re-perfusion TherapyPhase 4 · Taichung Veterans General Hospital
Studies
Open first, then newest update. How each study uses Canagliflozin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 122
- Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial CancerNot yet recruitingPhase 2Wang YingmeiNCT07890064Written as CanagliflozinHow we know
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as InvokanaHow we know
- Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid CancerRecruitingPhase 1West China HospitalNCT07703163Written as CanagliflozinHow we know
- Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentRecruitingPhase 4Fudan UniversityNCT07711171Written as Canagliflozin groupHow we know
- CANagliflozin In DIALysis PatientsNot yet recruitingPhase 4University Medical Center GroningenNCT07527390Written as Invokana 300 mg and 100 mg tabletHow we know
- Canagliflozin Targeting Vascular InflammationRecruitingPhase 2/3Ottawa Heart Institute Research CorporationNCT05427084Written as CanagliflozinHow we know
- SGLT2 Inhibitor Utilization Re-perfusion TherapyNot yet recruitingPhase 4Taichung Veterans General HospitalNCT06858436Written as Canagliflozin 100mgHow we know
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRecruitingPhase 2National Taiwan University HospitalNCT06528405Written as canagliflozinHow we know
- Canagliflozin in Advanced Renal Disease With MRI EndpointsRecruitingPhase 2McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06182839Written as Canagliflozin 300Mg TabHow we know
- Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal CancerRecruitingPhase 1West China HospitalNCT07076823Written as CanagliflozinHow we know
- Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary SyndromeNot yet recruitingPhase 4Ping Li,MDNCT06256289Written as Canagliflozin 100mg TabHow we know
- Canagliflozin With Gemcitabine in Pancreatic CarcinomaNot yet recruitingNot applicableZhang Xiaofeng,MDNCT05903703Written as Canagliflozin and GemcitabineHow we know
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedPhase 4Fundación para la Investigación del Hospital Clínico de ValenciaNCT06851962Written as CanagliflozinHow we know
- Safety and Efficacy of Canagliflozin in Advanced CKDCompletedPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT05309785Written as Invokana 300 mg and 100 mg tabletHow we know
- Renal Mechanism of SGLT2 InhibitionActive, not recruitingPhase 2University of Colorado, DenverNCT05507892Written as canagliflozinHow we know
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedPhase 4Tanabe Pharma CorporationNCT02220920Written as Canagliflozin (TA-7284)How we know
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesCompletedPhase 3Tanabe Pharma CorporationNCT01413204Written as TA-7284 LowHow we know
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesCompletedPhase 2Tanabe Pharma CorporationNCT01022112Written as TA-7284-LowHow we know
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedPhase 4Tanabe Pharma CorporationNCT02227849Written as Canagliflozin (TA-7284)How we know
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedPhase 4Tanabe Pharma CorporationNCT02622113Written as Canagliflozin (TA-7284)How we know
See all 122 studies that test Canagliflozin →
Given beside what is tested · 5 — Canagliflozin is usual care or a partner of the new treatment
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05090358Written as CanagliflozinHow we know
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)CompletedPhase 3Tanabe Pharma CorporationNCT02354235Written as CanagliflozinHow we know
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)CompletedPhase 3Tanabe Pharma CorporationNCT02354222Written as CanagliflozinHow we know
- Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesCompletedPhase 3Tanabe Pharma CorporationNCT02220907Written as Teneligliptin/CanagliflozinHow we know
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknownPhase 1/2Petra PharmaNCT04073680Written as Canagliflozin 300mgHow we know
As the comparator · 2 — what is tested is compared with Canagliflozin
- Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 DiabetesStatus unknownPhase 4Nanjing First Hospital, Nanjing Medical UniversityNCT05856578Written as CanagliflozinHow we know
- Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT03136484Written as CanagliflozinHow we know
What changed recently
From the registry's own updates since Oct 21, 2026.
Newly registered1
Codes
What other systems call Canagliflozin · ClinicalTrials.gg INT006557
- MeSH (NLM) D000068896CanagliflozinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0SAC974Z85CANAGLIFLOZINConfirmed FDA, NLM, Wikidata
- RxNorm 1373458Confirmed FDA, Wikidata
- Wikidata Q47495780canagliflozin hemihydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91018CanagliflozinConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068896 | Canagliflozin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0SAC974Z85 | CANAGLIFLOZIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1373458 | — | Confirmed FDA, Wikidata |
| Wikidata | Q47495780 | canagliflozin hemihydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91018 | Canagliflozin | Confirmed FDA, Wikidata |
Also registered as canagliflozin anhydrous (UNII 6S49DGR869 · RxNorm 1546031).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.